Higher mycological cure rates with OXISTAT Lotion in tinea pedis vs vehicle*^1,2
(demonstrated 2 weeks post 4-week treatment)

Mycological cure¹

• No evidence (culture and potassium hydroxide [KOH] preparation) of the original pathogen

Higher rates of treatment success with OXISTAT Lotion in tinea pedis vs vehicle*^1,2
(demonstrated 2 weeks post 4-week treatment)

Treatment success¹

• Global evaluation of 90% clinical improvement
• Microbiological eradication

In a clinical trial of 269 patients treated with OXISTAT Lotion, the most common adverse events were burning and stinging (0.7% each) and pruritus, scaling, tingling, pain, and dyshidrotic eczema (0.4% each).¹

* In a clinical trial of OXISTAT Lotion involving 332 evaluable patients with clinically and microbiologically established tinea pedis, OXISTAT Lotion showed no trace of fungal infections in lab tests (in 67% when used twice daily and 64% when used once daily, compared with 28% patients using lotion without medicine) and almost complete symptom improvement and no trace of fungal infection in lab tests (in 41% when used twice daily and 34% when used once daily, compared with 10% of patients using lotion without medicine).¹

References: 1. OXISTAT Lotion Prescribing Information; July 2022. 2. Data on file, ANI Pharmaceuticals, Inc.